John Hamm, MD
Medical Oncology · Louisville, KYNPI 1023075660
Payments from drug & device makers
Across 615 payments — averaging $5278.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$964K
- AstraZeneca$508K
- Biontech SE$247K
- Boehringer Ingelheim International GmbH$227K
- Amgen$197K
- Seagen Inc.$184K
- plus $920K from 24 others
Across 10 payments — averaging $416.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3K
- F. Hoffmann-la Roche AG$1K
- AbbVie$92
- Eli Lilly$26
What the payments were for
- Consulting fees$7,19427%
- Speaking & faculty fees$15,15558%
- Travel & lodging$2,4519%
- Food & beverage$1,4335%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 117 | $963,581 |
| AstraZeneca | 30 | $508,194 |
| Biontech SE | 97 | $246,801 |
| Boehringer Ingelheim International GmbH | 19 | $226,620 |
| Amgen | 4 | $196,542 |
| Seagen Inc. | 29 | $184,034 |
| Merck | 8 | $176,096 |
| AbbVie | 88 | $132,727 |
| Eli Lilly | 7 | $95,564 |
| Genmab U.S., Inc. | 15 | $59,312 |
| Astrazeneca UK Limited | 10 | $55,642 |
| F. Hoffmann-la Roche AG | 25 | $47,286 |
| Novocure Inc. | 12 | $45,327 |
| Genentech, Inc. | 30 | $44,736 |
| Sanofi US Services Inc. | 5 | $44,678 |
| Regeneron | 7 | $40,377 |
| EMD Serono, Inc. | 20 | $37,542 |
| Genmab A/s | 10 | $30,912 |
| Merck Healthcare Kgaa | 7 | $29,195 |
| E.r. Squibb & Sons, L.L.C. | 3 | $24,692 |
| Deciphera Pharmaceuticals Inc. | 6 | $18,070 |
| Bristol Myers Squibb | 2 | $10,245 |
| Incyte Corporation | 13 | $9,198 |
| Jazz Pharmaceuticals Inc. | 5 | $7,885 |
| Exelixis Inc. | 9 | $4,447 |
| Chugai Pharmaceutical Co., Ltd. | 2 | $2,843 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 31 | $2,449 |
| Puma Biotechnology, Inc. | 2 | $1,125 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPZELCA$7,885
- Cabometyx$4,306
- IMFINZI$3,450
- Nerlynx$1,125
- IMDELLTRA (AMG 757)$121
How this compares
$3,246,149 in reported general payments places this provider in the 90th percentile of 53 medical oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 40 | $582,992 |
| RevlimidLenalidomide | 22 | $464,500 |
| TagrissoOsimertinib Mesylate | 13 | $221,099 |
| LumakrasSotorasib | 12 | $202,732 |
| JakafiRuxolitinib Phosphate | 11 | $193,062 |
| Everolimus | 13 | $33,408 |
| EliquisApixaban | 38 | $26,221 |
| Ondansetron Hcl | 138 | $3,726 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 44 | $1,810 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 67 | $1,147 |
| Morphine Sulfate ErMorphine Sulfate | 15 | $732 |
| Dexamethasone | 70 | $620 |
| Megestrol Acetate | 12 | $540 |
| Levothyroxine Sodium | 64 | $474 |
| Pantoprazole Sodium | 65 | $412 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $963,581 | $609,21278 claims |
| Bristol Myers SquibbRevlimid | $10,245 | $464,50022 claims |
| AstraZenecaTagrisso | $508,194 | $221,09913 claims |
| AmgenLumakras | $196,542 | $202,73212 claims |
| Incyte CorporationJakafi | $9,198 | $193,06211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 53 medical oncology providers in Kentucky.
Other medical oncology in Louisville
- Don StevensLouisville$16M
- Michael DriscollLouisville$3.6M
- Joseph FlynnLouisville$537K
- Renato la RoccaLouisville$360K
- Douglas NelsonLouisville$82K
- Emmanuel NidhiryLouisville$67K
- Janell SeegerLouisville$24K
- Vijay RaghavanLouisville$17K
- Subhash ShethLouisville$1K
- Thomas WoodcockLouisville$57
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.